These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16370383)

  • 41. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
    Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
    J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical trials referral resource. Tumor vaccine clinical trials.
    Cheson BD; Sznol M; Phillips PH
    Oncology (Williston Park); 1995 Oct; 9(10):929, 931. PubMed ID: 8573477
    [No Abstract]   [Full Text] [Related]  

  • 43. Immunopathogenesis and immunotherapy of multiple sclerosis.
    Hemmer B; Nessler S; Zhou D; Kieseier B; Hartung HP
    Nat Clin Pract Neurol; 2006 Apr; 2(4):201-11. PubMed ID: 16932551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DNA plasmid vaccination for multiple sclerosis.
    Stüve O; Eagar TN; Frohman EM; Cravens PD
    Arch Neurol; 2007 Oct; 64(10):1385-6. PubMed ID: 17923622
    [No Abstract]   [Full Text] [Related]  

  • 45. From exotic spice to modern drug?
    Singh S
    Cell; 2007 Sep; 130(5):765-8. PubMed ID: 17803897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders.
    Geerts H
    Curr Opin Investig Drugs; 2008 Jul; 9(7):800-11. PubMed ID: 18600585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
    Drane D; Gittleson C; Boyle J; Maraskovsky E
    Expert Rev Vaccines; 2007 Oct; 6(5):761-72. PubMed ID: 17931156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
    Peppard WJ; Schuenke CD
    Curr Opin Investig Drugs; 2008 Feb; 9(2):210-25. PubMed ID: 18246524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myelin basic protein administration in multiple sclerosis.
    Campbell B; Vogel PJ; Fisher E; Lorenz R
    Arch Neurol; 1973 Jul; 29(1):10-5. PubMed ID: 4123119
    [No Abstract]   [Full Text] [Related]  

  • 52. Pharmacogenomics in the evaluation of efficacy and adverse events during clinical development of vaccines.
    Nilsson LJ; Regnström KJ
    Methods Mol Biol; 2008; 448():469-79. PubMed ID: 18370243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection.
    Habersetzer F; Baumert TF; Stoll-Keller F
    Curr Opin Mol Ther; 2009 Aug; 11(4):456-62. PubMed ID: 19649991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.
    Fock KM; Ang TL
    Curr Opin Investig Drugs; 2008 Oct; 9(10):1108-15. PubMed ID: 18821474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methodology of clinical trials in multiple sclerosis.
    Mitsikostas DD
    Neurol Sci; 2006 Sep; 27 Suppl 5():S362-4. PubMed ID: 16998721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmaceutical aspects of combined vaccines: a manufacturer's perspective.
    Vose JR
    Biologicals; 1994 Dec; 22(4):335-8. PubMed ID: 7779359
    [No Abstract]   [Full Text] [Related]  

  • 57. The Immunotherapeutics & Vaccine Summit--CHI's fourth annual meeting. Preclinical/clinical development of immunotherapies and vaccines. 17-19 August 2009, Providence, RI, USA.
    Butterfield LH
    IDrugs; 2009 Oct; 12(10):633-5. PubMed ID: 19790013
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 'Inverse vaccines' could treat autoimmune disease - from multiple sclerosis to celiac disease.
    Arnold C
    Nat Med; 2024 May; 30(5):1218-1219. PubMed ID: 38600260
    [No Abstract]   [Full Text] [Related]  

  • 59. Questions for European Vaccine Initiative.
    Leroy O
    Hum Vaccin; 2010 Jun; 6(6):435. PubMed ID: 20671436
    [No Abstract]   [Full Text] [Related]  

  • 60. The inverse of immunity.
    Dolgin E
    Nat Med; 2010 Jul; 16(7):740-3. PubMed ID: 20613744
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.